Small-cap Healthcare company NeoGenomics has logged a 2.5% change today on a trading volume of 282,898. The average volume for the stock is 1,271,963.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. Based in Fort Myers, United States the company has 2,000 full time employees and a market cap of $1,420,908,800.
The company is now trading -28.71% away from its average analyst target price of $15.78 per share. The 9 analysts following the stock have set target prices ranging from $10 to $26, and on average give NeoGenomics a rating of buy.
Over the last year, NEO shares have gone down by -53.1%, which represents a difference of -40.4% when compared to the S&P 500. The stock's 52 week high is $24.46 per share and its 52 week low is $6. With its gross margins declining an average -10.4% over the last four years, NeoGenomics may not have a strong enough business to reverse this trend.
|Date Reported||Revenue ($ MM)||Cost of Revenue ($ MM)||Gross Margins (%)||YoY Growth (%)|